Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: marks (231), results (1000)

mini-RCHOP 21

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-RITUXIMAB-VINCRISTINE (mini-RCHOP 21) Re
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/mini-RCHOP-21.pdf

Cabazitaxel-Prednisolone

Description: Chemotherapy Protocol PROSTATE CABAZITAXEL-PREDNISOLONE Regimen • Prostate-Cabazitaxel-Prednisolone Indication • Castrate resistant metastatic prostate cancer previously treated with docetaxel containing regimens
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Cabazitaxel-Prednisolone.pdf

Cabozantinib

Description: Chemotherapy Protocol RENAL CELL CANCER Regimen CABOZANTINIB • Renal Cell – Cabozantinib (60mg-tablets) Indication • Cabozantinib s indicated for the treatment of advanced
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Cabozantinib.pdf

InP DoxorubicinIfosfamideVer1

Description: Chemotherapy Protocol SARCOMA DOXORUBICIN-IFOSFAMIDE In-Patient Regimen Regimen Sarcoma – InP-Doxorubicin - Ifosfamide Indication Soft tissue sarcoma WHO performance status 0
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InPDoxorubicinIfosfamideVer1.pdf

Cyclophosphamide-Doxorubicin-Paclitaxel

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOXORUBICIN-PACLITAXEL (21 day) Regimen • Breast Cancer – Cyclophosphamide-Doxorubicin-Paclitaxel (21 day) Indication • Neoadjuvant / adjuvant therapy
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Cyclophosphamide-Doxorubicin-Paclitaxel.pdf

Thyroid Cabozantinib

Description: Chemotherapy Protocol THYROID CANCER Regimen CABOZANTINIB • Thyroid – Cabozantinib (140mg-capsules) Indication • Unresectable, locally advanced or metastatic thyroid cancer where the disease
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Endocrinecancer/Thyroid-Cabozantinib.pdf

DRD Daratumumab-Lenalidomide-Dexamethasone

Description: Chemotherapy Protocol Myeloma DRD Daratumumab-Lenalidomide-Dexamethasone Regimen • Myeloma – DRD Daratumumab-Lenalidomide-Dexamethasone Indication • Daratumumab in combination with lenalidomide and dexamethasone
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DRD-Daratumumab-Lenalidomide-Dexamethasone.pdf

Rituximab-Gemcitabine-Oxaliplatin (R-GemOx)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB-GEMCITABINE-OXALIPLATIN (R-GemOx) Regimen • Lymphoma – Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) Indication • Salvage regimen for relapsed/refractory
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-Gemcitabine-Oxaliplatin-R-GemOx.pdf

Ibrutinib (MCL) (560mg)

Description: Chemotherapy Protocol Mantle Cell Lymphoma Regimen Ibrutinib • MCL – Ibrutinib (560mg) Indication • Mantle Cell Lymphoma with cyclin D1 overexpression or translocation breakpoints
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Ibrutinib-MCL-560mg.pdf

Paclitaxel (14day)

Description: Chemotherapy Protocol SARCOMA PACLITAXEL (14 day) Regimen • Sarcoma – Paclitaxel (14 day) Indication • Second line treatment of Kaposi sarcoma • WHO Performance status
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/Paclitaxel14day.pdf

261 to 270 of 548

Previous … 25 26 27 28 29 … Next